Cargando…

Modulation of VCAM-1 expression with antisense oligonucleotides targeting signalling molecules

Detalles Bibliográficos
Autores principales:	Morel, J, Park, CC, Combe, B, Zhu, K, Koch, AE
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833673/ http://dx.doi.org/10.1186/ar736

Ejemplares similares

Signaling pathways involved in IL-18 induced VCAM-1 expression in RA synovial fibroblasts
por: Morel, J, et al.
Publicado: (2002)

Targeting sphingosine kinase 1 with LNA oligonucleotides in gastric cancer
por: Füreder, Thorsten, et al.
Publicado: (2008)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

Targeting TGFβ Signaling to Address Fibrosis Using Antisense Oligonucleotides
por: March, James T., et al.
Publicado: (2018)

Improved targeting of miRNA with antisense oligonucleotides
por: Davis, Scott, et al.
Publicado: (2006)

TRAIL-induced rheumatoid arthritis fibroblast-like synoviocyte proliferation is inhibited by OPG
por: Morel, J, et al.
Publicado: (2004)

Systematic Approach to Developing Splice Modulating Antisense Oligonucleotides
por: Aung-Htut, May T., et al.
Publicado: (2019)

Fluorinated Nucleotide Modifications Modulate Allele Selectivity of SNP-Targeting Antisense Oligonucleotides
por: Østergaard, Michael E., et al.
Publicado: (2017)

Mechanisims of asthma and allergic disease – 1093. A novel human anti-VCAM-1 Monoclonal antibody Ameliorates airway inflammation and remodeling in murine asthma model
por: Lee, Jae-Hyun, et al.
Publicado: (2013)

Managing the sequence-specificity of antisense oligonucleotides in drug discovery
por: Hagedorn, Peter H., et al.
Publicado: (2017)

Defining the Factors That Contribute to On-Target Specificity of Antisense Oligonucleotides
por: Lima, Walt F., et al.
Publicado: (2014)

Targeted delivery of antisense oligonucleotides to pancreatic β-cells
por: Ämmälä, C., et al.
Publicado: (2018)

Effects of combinations of gapmer antisense oligonucleotides on the target reduction
por: Yanagidaira, Mitsugu, et al.
Publicado: (2023)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Inactivating Gene Expression with Antisense Modified Oligonucleotides
por: Altman, Sidney, et al.
Publicado: (2021)

Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression
por: Lim, Kian Huat, et al.
Publicado: (2020)

JunD/HBZ enhances HBZ enhances HTLV-1 antisense transcription
por: Peloponese, Jean-Marie, et al.
Publicado: (2011)

Mannosylated Chitosan Nanoparticles for Delivery of Antisense Oligonucleotides for Macrophage Targeting
por: Shilakari Asthana, Gyati, et al.
Publicado: (2014)

Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics
por: Le, Bao T., et al.
Publicado: (2018)

Antisense oligonucleotides targeting angiotensinogen: insights from animal studies
por: Wu, Chia-Hua, et al.
Publicado: (2019)

Selective targeting of MYC mRNA by stabilized antisense oligonucleotides
por: Gill, Taylor, et al.
Publicado: (2021)

Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2
por: Gagliardi, Maria, et al.
Publicado: (2022)

Use of antisense oligonucleotides to target Notch3 in skeletal cells
por: Canalis, Ernesto, et al.
Publicado: (2022)

Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides
por: Wang, Dali, et al.
Publicado: (2022)

Cyclodextrin-Based Nanoparticles for Delivery of Antisense Oligonucleotides Targeting Huntingtin
por: Mendonça, Monique C. P., et al.
Publicado: (2023)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023)

In-silico study of antisense oligonucleotide antibiotics
por: Chen, Erica S., et al.
Publicado: (2023)

Rational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation
por: Shao, Yu, et al.
Publicado: (2006)

Engineering T cells and molecules for targeting joints and inflammation
por: Chernajovsky, Y, et al.
Publicado: (2001)

Identifying and avoiding off-target effects of RNase H-dependent antisense oligonucleotides in mice
por: Hagedorn, Peter H, et al.
Publicado: (2018)

Delivery of antisense constructs and ribozymes to inhibit cartilage destruction in the SCID mouse model of RA
por: Pap, T, et al.
Publicado: (2001)

The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides
por: Ming, Xin, et al.
Publicado: (2013)

Antisense oligonucleotides delivered to the amniotic cavity in utero modulate gene expression in the postnatal mouse
por: Depreux, Frederic F., et al.
Publicado: (2016)

Hypergravity Increases Blood–Brain Barrier Permeability to Fluorescent Dextran and Antisense Oligonucleotide in Mice
por: Dubayle, David, et al.
Publicado: (2023)

IL-13 overexpression during immune complex arthritis diminishes MMP-mediated VDIPEN expression
por: Nabbe, KC, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_j7lfpmfpd485dk9n0b1lvgpedu